Sanofi Pasteur MSD

IMOVAX (Inactivated Poliomyelitis vaccine) is an inactivated poliovirus vaccine developed by Sanofi Pasteur for the prevention of poliomyelitis. The program, designated IPV25, is classified as a monoclonal antibody modality vaccine candidate currently in Phase 2 development. As of the latest disclosed milestone on January 22, 2014, the program has completed Phase 2 activities. The vaccine is indicated for poliomyelitis prevention and represents part of Sanofi Pasteur's broader immunization portfolio. IMOVAX is associated with the combination vaccine INFANRIX HEXA, which contains inactivated poliovirus vaccine as one of six active components and has received European regulatory approval. The competitive landscape includes multiple approved combination and standalone vaccines targeting poliomyelitis and related infectious diseases. Sanofi Pasteur's development strategy appears focused on combination formulations that integrate IPV with other routine childhood immunizations, enhancing clinical utility and market positioning.

Poliomyelitis remains a significant global public health concern despite decades of vaccination efforts. The disease, caused by poliovirus, can result in permanent paralysis and death, particularly in unvaccinated or under-vaccinated populations. Inactivated poliovirus vaccines (IPV) are critical components of routine childhood immunization schedules worldwide and are essential for maintaining polio-free status in regions that have achieved eradication. The integration of IPV into combination vaccines like INFANRIX HEXA addresses the clinical need for simplified immunization schedules that reduce the number of injections required for comprehensive protection against multiple diseases. This approach improves vaccination compliance, particularly in resource-limited settings where healthcare infrastructure may be constrained. The market for poliomyelitis vaccines remains substantial due to universal childhood immunization requirements across developed and developing nations. Sanofi Pasteur's positioning in this space leverages its established expertise in vaccine development and manufacturing. The competitive landscape includes multiple approved alternatives, underscoring the importance of differentiation through combination formulations, improved safety profiles, or enhanced immunogenicity. As global polio eradication initiatives continue, demand for reliable, effective IPV formulations remains consistent across diverse healthcare systems.

Drug Class: Inactivated viral vaccine

Modality: Monoclonal antibody (as classified in the program data)

Mechanism of Action: Not yet disclosed

Target: Not yet disclosed

Route of Administration: Not yet disclosed

Related Therapies: IMOVAX is incorporated into INFANRIX HEXA, a hexavalent combination vaccine containing diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus, and Haemophilus influenzae type-b conjugate antigens. Other approved poliomyelitis vaccines and combination formulations exist in the competitive landscape, including HEXYON and TRITANRIX HEPB.

First Approval: INFANRIX HEXA received European approval; specific approval date for IMOVAX as a standalone product is not yet disclosed.

Patent Status: Not yet disclosed

European Union: INFANRIX HEXA, which contains inactivated poliovirus vaccine (IMOVAX component), received European approval. The product is authorized by the European Medicines Agency (EMA) under EMEA/H/C/000296, with Marketing Authorization Holder listed as GlaxoSmithKline Biologicals S.A. Authorisation date recorded as 12/02/2026.

United States (FDA): Regulatory status not yet disclosed.

China (NMPA): Clinical trial activity is ongoing in China. Multiple inactivated vaccine formulations are in clinical trials, with NCT IDs NCT01244464, NCT03001986, NCT05148949, NCT05198336, and NCT05365724 registered. Additional vaccine trials are registered under NCT01507857, NCT02003495, NCT02302170, NCT03357289, and NCT07077356.

Japan (PMDA): Regulatory status not yet disclosed.

Strategic Positioning: Sanofi Pasteur's development of IMOVAX within the INFANRIX HEXA combination vaccine reflects a market strategy focused on clinical convenience and simplified immunization schedules. By integrating inactivated poliovirus vaccine with five other antigens, the company addresses healthcare provider and patient preferences for reduced injection burden while maintaining comprehensive protection against multiple diseases.

Development Status: The completion of Phase 2 activities as of January 2014 indicates that IMOVAX has progressed through early-stage clinical evaluation. However, the absence of disclosed Phase 3 initiation or regulatory filing milestones suggests either ongoing development, transition to combination vaccine formulation studies, or potential discontinuation of standalone development in favor of the hexavalent formulation.

Competitive Implications: The poliomyelitis vaccine market is mature and highly competitive, with multiple approved alternatives available globally. IMOVAX does not appear to offer novel mechanisms of action or breakthrough efficacy claims. Differentiation relies on formulation convenience and integration with other routine immunizations rather than pharmacological innovation. The presence of established competitors like HEXYON and TRITANRIX HEPB indicates market saturation in the combination vaccine space.

Regulatory Pathway: The approval of INFANRIX HEXA in Europe demonstrates successful regulatory navigation for the combination formulation. However, the lack of disclosed FDA approval or other major regulatory approvals suggests potential geographic limitations or ongoing regulatory engagement.

Future Catalysts: Expected milestones are not yet disclosed. Potential catalysts include Phase 3 initiation or completion, regulatory filings in additional jurisdictions (particularly the United States), label expansions to additional age groups or populations, and manufacturing scale-up announcements.